Abstract
The renin-angiotensin-aldosterone system blockade is a key component in the modern management of cardiovascular diseases. Agents that interfere with the different components of this system such as angiotensin converting enzyme inhibitors, sartans and mineralocorticoid receptor antagonists represent valuable therapeutic tools to reduce cardiovascular risk in brachial blood pressure independent mechanisms. Indeed, antagonists of the renin-angiotensin-aldosterone system reduce inflammation, oxidative stress and vascular remodeling in hypertension beyond blood pressure reduction and have demonstrated better cardiovascular protection compared with some of the other antihypertensive agents, especially in selected populations such as patients with diabetes and renal failure. These advantages were confirmed recently in several large-scale randomized trials. Latest evidence suggests that the effect of some antihypertensive drugs on central blood pressure is greater when compared with the effect on peripheral pressure. Nowadays, there is growing agreement that relatively greater influence of agents blocking renin-angiotensin system on central blood pressure may at least partly explain their advantages over other antihypertensives in many clinical situations. Clinical consequences of overestimation of the antihypertensive effect of some drug classes and underestimation blood pressure changes in patients treated with angiotensin converting enzyme inhibitors when analyzing brachial instead of central blood pressure is being increasingly recognized recently.
Keywords: Renin-angiotensin-aldosterone system, angiotensin converting enzyme inhibitors, sartans, mineralocorticoid receptor antagonists, hypertension, central blood pressure, cardiovascular risk, pleiotropic effects
Current Pharmaceutical Design
Title: Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System
Volume: 15 Issue: 5
Author(s): P. Jankowski, M. E. Safar and A. Benetos
Affiliation:
Keywords: Renin-angiotensin-aldosterone system, angiotensin converting enzyme inhibitors, sartans, mineralocorticoid receptor antagonists, hypertension, central blood pressure, cardiovascular risk, pleiotropic effects
Abstract: The renin-angiotensin-aldosterone system blockade is a key component in the modern management of cardiovascular diseases. Agents that interfere with the different components of this system such as angiotensin converting enzyme inhibitors, sartans and mineralocorticoid receptor antagonists represent valuable therapeutic tools to reduce cardiovascular risk in brachial blood pressure independent mechanisms. Indeed, antagonists of the renin-angiotensin-aldosterone system reduce inflammation, oxidative stress and vascular remodeling in hypertension beyond blood pressure reduction and have demonstrated better cardiovascular protection compared with some of the other antihypertensive agents, especially in selected populations such as patients with diabetes and renal failure. These advantages were confirmed recently in several large-scale randomized trials. Latest evidence suggests that the effect of some antihypertensive drugs on central blood pressure is greater when compared with the effect on peripheral pressure. Nowadays, there is growing agreement that relatively greater influence of agents blocking renin-angiotensin system on central blood pressure may at least partly explain their advantages over other antihypertensives in many clinical situations. Clinical consequences of overestimation of the antihypertensive effect of some drug classes and underestimation blood pressure changes in patients treated with angiotensin converting enzyme inhibitors when analyzing brachial instead of central blood pressure is being increasingly recognized recently.
Export Options
About this article
Cite this article as:
Jankowski P., Safar E. M. and Benetos A., Pleiotropic Effects of Drugs Inhibiting the Renin-Angiotensin-Aldosterone System, Current Pharmaceutical Design 2009; 15 (5) . https://dx.doi.org/10.2174/138161209787315747
DOI https://dx.doi.org/10.2174/138161209787315747 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Bariatric Surgery - Effects on Obesity and Related co-Morbidities
Current Diabetes Reviews Predictive Genomics DNA Profiling for Athletic Performance
Recent Patents on DNA & Gene Sequences Hallmarks in the Therapeutic Approach of Aortic Aneurysms: The Main Contributors
Current Pharmaceutical Design Epidemiological Features of the 2019 Novel Coronavirus Outbreak in China
Current Topics in Medicinal Chemistry Formulation Development, Statistical Optimization and Characterization of the Self-Microemulsifying Drug Delivery System (SMEDDS) of Irbesartan
Nanoscience & Nanotechnology-Asia Utility of Anti-Arrhythmic Medications in ‘Lone Atrial Fibrillation’
Current Pharmaceutical Design Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Antiatherosclerotic and Cardioprotective Effects of Time-Released Garlic Powder Pills
Current Pharmaceutical Design Endothelial to Mesenchymal Transition in the Cardiogenesis and Cardiovascular Diseases
Current Cardiology Reviews The Efficacy and Safety of Cilnidipine on Mild to Moderate Essential Hypertension: A Systematic Review and Meta-analysis of Randomized Controlled Trials in Chinese Patients
Cardiovascular & Hematological Disorders-Drug Targets Osteoblastic Responses to LPS, Glucose-oxidised LDL and Minocycline: Therapeutic Targets for Periodontal and Cardiometabolic Diseases
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Inhibitory Effect of Some Algerian Plants Phenolics Extracts on the α - glucosidase and α - amylase Activities and their Antioxidant Activities
Current Enzyme Inhibition Diabetic CVD – Soluble Epoxide Hydrolase as A Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Recent Advances in GNAS Epigenetic Research of Pseudohypoparathyroidism
Current Molecular Medicine Modeling the Interactions Between α1-Adrenergic Receptors and Their Antagonists
Current Computer-Aided Drug Design Vascular Biomarkers in Asthma and COPD
Current Topics in Medicinal Chemistry Management of Idiopathic Intracranial Hypertension During the COVID-19 Pandemic
Reviews on Recent Clinical Trials Sex Impact on Biomarkers, Pharmacokinetics and Pharmacodynamics
Current Medicinal Chemistry